公开(公告)号：US20180250394A1

公开(公告)日：2018-09-06

申请号：US15372951

申请日：2016-12-08

Applicant: Genentech, Inc.

Inventor： Steffen Durinck ,  Bijay Jaiswal ,  Zora Modrusan ,  Somasekar Seshagiri ,  Eric Stawiski ,  Na Zhang

IPC: A61K39/395 ,  A61P35/00 ,  A61P13/12 ,  G01N33/574

CPC classification number: A61K39/39558 ,  A61K2039/505 ,  A61K2039/5152 ,  A61K2039/545 ,  A61P13/12 ,  A61P35/00 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/574 ,  G01N2800/50 ,  G01N2800/60 ,  G01N2800/7028

Abstract: Provided are therapies related to the treatment of pathological conditions, such as cancer.

公开(公告)号：US20210025008A1

公开(公告)日：2021-01-28

申请号：US16895395

申请日：2020-06-08

Applicant: Genentech, Inc.

Inventor： Frederic J. de Sauvage ,  Eric William Stawiski ,  Steffen Durinck ,  Zora Modrusan ,  Somasekar Seshagiri

IPC: C12Q1/6886 ,  C07K14/415 ,  A61K39/395 ,  A61K45/06

Abstract: Provided are therapies related to the treatment of pathological conditions, such as cancer.

公开(公告)号：US20150290196A1

公开(公告)日：2015-10-15

申请号：US14625138

申请日：2015-02-18

Applicant: GENENTECH, INC.

Inventor： Somasekar Seshagiri

IPC: A61K31/517 ,  C12Q1/68 ,  A61K45/06

Abstract: The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.

Abstract translation: 本发明涉及表皮生长因子受体（EGFR）中的突变和检测这种突变的方法以及用于鉴定对抗癌治疗如化疗和/或激酶抑制剂治疗敏感的肿瘤的预后方法。 所述方法包括确定肿瘤样品中突变的EGFR基因或突变的EGFR蛋白的存在，由此突变的EGFR基因或蛋白质的存在表明肿瘤易于治疗。

公开(公告)号：US20170065588A1

公开(公告)日：2017-03-09

申请号：US15237412

申请日：2016-08-15

Applicant: Genentech, Inc.

Inventor： Kui Lin ,  Elizabeth Punnoose ,  Somasekar Seshagiri

IPC: A61K31/517 ,  C12Q1/68 ,  A61K31/58 ,  G01N33/574

CPC classification number: A61K31/517 ,  A61K31/58 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N33/5748

Abstract: Provided herein are biomarkers, and combinations of biomarkers, for predicting sensitivity to cancer treatments.

Abstract translation: 本文提供了用于预测对癌症治疗的敏感性的生物标志物和生物标志物的组合。

公开(公告)号：US08987266B2

公开(公告)日：2015-03-24

申请号：US13972527

申请日：2013-08-21

Applicant: Genentech, Inc.

Inventor： Somasekar Seshagiri

IPC: C12Q1/68 ,  C12Q1/48 ,  G01N33/574 ,  A61K31/19 ,  A61K31/498 ,  A61K31/517 ,  A61K31/704 ,  A61K31/7072

CPC classification number: A61K31/517 ,  A61K31/19 ,  A61K31/498 ,  A61K31/704 ,  A61K31/7072 ,  A61K45/06 ,  C12Q1/485 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/16 ,  G01N33/57492 ,  G01N2333/71 ,  G01N2500/00

Abstract: The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.

Abstract translation: 本发明涉及表皮生长因子受体（EGFR）中的突变和检测这种突变的方法以及用于鉴定对抗癌治疗如化疗和/或激酶抑制剂治疗敏感的肿瘤的预后方法。 所述方法包括确定肿瘤样品中突变的EGFR基因或突变的EGFR蛋白的存在，由此突变的EGFR基因或蛋白质的存在表明肿瘤易于治疗。

公开(公告)号：US20150010537A1

公开(公告)日：2015-01-08

申请号：US14199738

申请日：2014-03-06

Applicant: Genentech, Inc.

Inventor： Zhengyan Kan ,  Denise M. Kenski ,  Brock Peters ,  Somasekar Seshagiri

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/156

Abstract: Nucleotide and amino acid variations associated with tumors are provided. Methods for detecting variations and for diagnosing and treating tumors are provided.

Abstract translation: 提供了与肿瘤相关的核苷酸和氨基酸变异。 提供了检测变异和诊断和治疗肿瘤的方法。

公开(公告)号：US20130209473A1

公开(公告)日：2013-08-15

申请号：US13764631

申请日：2013-02-11

Applicant: Genentech, Inc.

Inventor： Frederic J. de Sauvage ,  Eric William Stawiski ,  Steffen Durinck ,  Zora Modrusan ,  Somasekar Seshagiri

IPC: C12Q1/68 ,  A61K45/06 ,  A61K39/395

Abstract: Provided are therapies related to the treatment of pathological conditions, such as cancer.

Abstract translation: 提供与治疗病理状况如癌症有关的疗法。

公开(公告)号：US20130195870A1

公开(公告)日：2013-08-01

申请号：US13694413

申请日：2012-11-29

Applicant: Genentech, Inc.

Inventor： Bijay Shankar Jaiswal ,  Somasekar Seshagiri

IPC: C12Q1/68 ,  A61K39/395 ,  A61K31/517

CPC classification number: C12Q1/6886 ,  A61K31/517 ,  A61K39/39558 ,  C12Q2600/112 ,  C12Q2600/156

Abstract: The present invention concerns somatic ErbB3 mutations in cancer including methods of identifying, diagnosing, and prognosing ErbB3 cancers, as well as methods of treating cancer, including certain subpopulations of patients.

Abstract translation: 本发明涉及癌症中的体细胞ErbB3突变，包括鉴定，诊断和预测ErbB3癌症的方法，以及治疗癌症的方法，包括患者的某些亚群。

公开(公告)号：US20200172631A1

公开(公告)日：2020-06-04

申请号：US16662939

申请日：2019-10-24

Applicant: GENENTECH, INC.

Inventor： Somasekar Seshagiri

IPC: C07K16/32 ,  G01N33/68 ,  G01N33/574 ,  A61K47/68

Abstract: The present disclosure relates to somatic ErbB2 mutations in cancer and provides methods of identifying, diagnosing, and prognosing ErbB2-positive cancers. The present disclosure further provides methods of treating cancer, including certain subpopulations of patients. The mutations are in the transmembrane domain or juxtamembrane domain of ErbB2.

公开(公告)号：US20180360835A1

公开(公告)日：2018-12-20

申请号：US16122713

申请日：2018-09-05

Applicant: Genentech, Inc.

Inventor： Kui Lin ,  Elizabeth Punnoose ,  Somasekar Seshagiri

IPC: A61K31/517 ,  A61K31/58 ,  G01N33/574 ,  C12Q1/6886

Abstract: Provided herein are biomarkers, and combinations of biomarkers, for predicting sensitivity to cancer treatments.